Literature DB >> 19006602

LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages.

Wilma A Stolk1, Sake J de Vlas, Gerard J J M Borsboom, J Dik F Habbema.   

Abstract

LYMFASIM is a simulation model for lymphatic filariasis transmission and control. We quantified its parameters to simulate Wuchereria bancrofti transmission by Anopheles mosquitoes in African villages, using a wide variety of reported data. The developed model captures the general epidemiological patterns, but also the differences between communities. It was calibrated to represent the relationship between mosquito biting rate and the prevalence of microfilariae (mf) in the human population, the age-pattern in mf prevalence, and the relation between mf prevalence and geometric mean mf intensity. Explorative simulations suggest that the impact of mass treatment depends strongly on the mosquito biting rate and on the assumed coverage, compliance and efficacy. Our sensitivity analysis showed that some biological parameters strongly influence the predicted equilibrium pre-treatment mf prevalence (e.g. the lifespan of adult worms and mf). Other parameters primarily affect the post-treatment trends (e.g. severity of density dependence in the mosquito uptake of infection from the human blood, between-person variability in exposure to mosquito bites). The longitudinal data, which are being collected for evaluation of ongoing elimination programmes, can help to further validate the model. The model can help to assess when ongoing elimination activities in African populations can be stopped and to design surveillance schemes. It can be a valuable tool for decision making in the Global Programme to Eliminate Lymphatic Filariasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006602     DOI: 10.1017/S0031182008000437

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  30 in total

1.  Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels.

Authors:  Benoit Dembele; Yaya I Coulibaly; Housseini Dolo; Siaka Konate; Siaka Y Coulibaly; Dramane Sanogo; Lamine Soumaoro; Michel E Coulibaly; Salif Seriba Doumbia; Abdallah A Diallo; Sekou F Traore; Adama Diaman Keita; Michael P Fay; Thomas B Nutman; Amy D Klion
Journal:  Clin Infect Dis       Date:  2010-11-01       Impact factor: 9.079

2.  Corallopyronin A specifically targets and depletes essential obligate Wolbachia endobacteria from filarial nematodes in vivo.

Authors:  Andrea Schiefer; Alexander Schmitz; Till F Schäberle; Sabine Specht; Christine Lämmer; Kelly L Johnston; Dmitry G Vassylyev; Gabriele M König; Achim Hoerauf; Kenneth Pfarr
Journal:  J Infect Dis       Date:  2012-05-14       Impact factor: 5.226

3.  Sequential modelling of the effects of mass drug treatments on anopheline-mediated lymphatic filariasis infection in Papua New Guinea.

Authors:  Brajendra K Singh; Moses J Bockarie; Manoj Gambhir; Peter M Siba; Daniel J Tisch; James Kazura; Edwin Michael
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

4.  Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control.

Authors:  Sammy M Njenga; Charles S Mwandawiro; C Njeri Wamae; Dunstan A Mukoko; Anisa A Omar; Masaaki Shimada; Moses J Bockarie; David H Molyneux
Journal:  Parasit Vectors       Date:  2011-05-25       Impact factor: 3.876

Review 5.  A research agenda for helminth diseases of humans: modelling for control and elimination.

Authors:  María-Gloria Basáñez; James S McCarthy; Michael D French; Guo-Jing Yang; Martin Walker; Manoj Gambhir; Roger K Prichard; Thomas S Churcher
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

6.  Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.

Authors:  Wilma A Stolk; Quirine A ten Bosch; Sake J de Vlas; Peter U Fischer; Gary J Weil; Ann S Goldman
Journal:  PLoS Negl Trop Dis       Date:  2013-01-03

7.  What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs.

Authors:  Randee J Kastner; Christopher M Stone; Peter Steinmann; Marcel Tanner; Fabrizio Tediosi
Journal:  PLoS Negl Trop Dis       Date:  2015-10-09

8.  African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases.

Authors:  Stanimira P Krotneva; Luc E Coffeng; Mounkaila Noma; Honorat G M Zouré; Lalle Bakoné; Uche V Amazigo; Sake J de Vlas; Wilma A Stolk
Journal:  PLoS Negl Trop Dis       Date:  2015-09-24

9.  Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges.

Authors:  Fabrizio Tediosi; Peter Steinmann; Don de Savigny; Marcel Tanner
Journal:  PLoS Negl Trop Dis       Date:  2013-11-07

Review 10.  A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis.

Authors:  Alison Krentel; Peter U Fischer; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.